Updating our readers more on the Bayer patent linkage case ,the Supreme Court on February 26,has refused to stay a Delhi High Court Order ,dated February 10. The said Order had rejected Bayer’s attempt to block the Drug Controller General of India from allowing Cipla Ltd. to market its generic version of Nexavar.
A notice has been issued to Cipla and the matter has been listed for further hearing in the third week of April.
We shall keep you updated on this.
The latest development is in today DNA news, Bayer’s plea has been considered by Supreme court. This brings into light the dispute of this linkage wherein DCGI and patent offices are two distinct bodies. DCGI’s sole purpose is to grant permission based on the data submitted by the applicant and international regulatory status of the molecule, for which the permission is being granted.